Publications

Relevant Research Publications in Accordance to Our Mission

1. Elucidate how the host macroenvironment both drives tumor development and heterogeneity and interacts with the tumor microenvironment to impact progression of ovarian and breast cancers
   • Huang T, Tworoger SS, Hecht JL, Rice MS, Sood AK, Kubzansky LD, Poole EM. Association of ovarian tumor β2-adrenergic receptor status with ovarian cancer risk factors and survival. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1587-1594. PMCID: PMC5135562.
   • Yang M, Prescott J, Poole EM, Rice MS, Kubzansky LD, Idahl A, Lundin E, DeVivo I, Tworoger SS. Pre-diagnosis leukocyte telomere length and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(3):339-345. PMCID: PMC5336400.
   • Peres LC, Mallen AR, Townsend MK, Poole EM, Trabert B, Allen NE, Arslan AA, Dossus L, Fortner RT, Gram IT, Hartge P, Idahl A, Kaaks R, Kvaskoff M, Magiocco A, Merritt MA14, Quirós JR, Tjonneland A, Trichopoulou A, Tumino R, van Gils C, Visvanathan K, Wentzensen N, Zeleniuch-Jacquotte A, Tworoger SS. High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium. Cancer Res. 2019. PMCID: 31462430.
   • Kim, S, Wang, M, Tyrer, JP, Jensen, A, Wiensch, A, Liu, G, Lee, AW, Ness, RB, Salvatore, M, Tworoger, SS, Whittemore, AS, Anton-Culver, H, Sieh W, Olson SH, Berchuck A, Goode EL, Goodman MT, Doherty JA, Chenevix‐Trench G, Rossing MA, Webb PM, Giles GG, Terry KL, Ziogas A, Fortner RT,  Menon U, Gayther SA, Wu AH, Song H, Brooks‐Wilson A, Bandera EV, Cook LS, Cramer DW, Milne RL, Winham SJ, Kjaer SK, Modugno F, Thompson PJ, Chang‐Claude J, Harris HR, Schildkraut JM, Le ND, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike MC, Pharoah PDP, Pearce CL, Mukherjee B. A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. Int J Cancer. 2019;144(9):2192–2205. doi:10.1002/ijc.32029
   • Huang T, Townsend MK, Wentzensen N, Trabert B, White E, Arslan AA, Weiderpass E, Buring JE, Clendenen TV, Giles GG, Lee IM, Milne RL, Onland-Moret NC, Peters U, Sandler DP, Schouten LJ, van den Brandt PA, Wolk A, Zeleniuch-Jacquotee A, Tworoger SS. Reproductive and hormonal factors and risk of ovarian cancer by tumor dominance: results from the Ovarian Cancer Cohort Consortium (OC3) Cancer Epidemiol Biomarkers Prev. 2019;cebp.0734.2019. doi:10.1158/1055-9965.EPI-19-0734
2. Identify and evaluate novel factors associated with ovarian cancer risk and survival, incorporating information about markers tumor heterogeneity
   • Barnard ME, Poole EM, Curhan GC, Eliassen AH, Rosner BA, Terry KL, Tworoger SS. Analgesic Use and Risk of Ovarian Cancer in the Nurses’ Health Studies. JAMA Onc. 2018;4(12):1675-1682. PMCID: PMC6400245.
   • Barnard ME, Hecht JL, Rice MS, Gupta M, Harris H, Eliassen AH, Rosner BA, Terry KL, Tworoger SS. NSAIDs and ovarian cancer risk by COX1/COX2 and macrophages. Cancer Epidemiol Biomarker Prev. 2018; 27(12):1509-1517. PMCID: PMC6415678.
   • Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL. Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J Cancer. 2016 Nov 22;115(11):1391-1399. PMCID: PMC5129827.
   • Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol. 2018;4(11):1519-1526. PMCID: PMC6248088.
   • Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian cancer risk factors by tumor aggressiveness: an analysis from the Ovarian Cancer Cohort Consortium. Int J Cancer. 2019 Jul 1; 145(1):58-69. PMCID: PMC6488363.
   • Rice MS, Poole EM, Willett WC, Tworoger SS. Adult dietary fat intake and ovarian cancer risk. Int J Cancer. 2019;10.1002/ijc.32635. doi:10.1002/ijc.32635
3. Develop and lead consortial research approaches, including being PI of the Ovarian Cancer Cohort Consortium
   • Wentzensen NA, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Butler LM, Chamosa S, Clendenen TV, Dossus L, Fortner R, Gapstur SM, Gaudet MM, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Jones M, Kaaks R, Kirsh V, Woon-Puay K, Lacey JV, Lee IM, Lundin E, Merritt MA, Onland- Moret NC, Peters U, Poynter JN, Rinaldi S, Robein K, Rohan T, Sandler DP, Schairer C, Schouten LJ, Sjoholm LK, Sieri S, Swerdlow A, Tjonneland A, Travis R, Trichopoulou A, van den Brandt P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS. Ovarian cancer Risk factors by histologic subtype: An analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016 20; 34(24):2888-98. PMCID: PMC5012665.
   • Trabert B, Poole EM, White E, Visvanathan K, Adami H-O, Anderson GL, Brasky, TM, Brinton, LA, Fortner, RT, Gaudet, M, Hartge, P, Hoffman-Bolton J, Jones, M, Lacey JV, Larsson SC, Mackenzie GG, Schouten LJ, Sandler, DP, O’Brien K, Patel AV, Peters U, Prizment AE, Robien K, Setiawan VW, Swerdlow A, van den Brandt PA, Weiderpass E,. Wilkens LR, Wolk A, Wentzensen N, Tworoger SS, on behalf of the Ovarian Cancer Cohort Consortium (OC3). Analgesic use and ovarian cancer risk: an analysis in the Ovarian Cancer Cohort Consortium. JNCI. 2019;111(2):137-145. PMCID: PMC6376910.
   • Ose J, Schock H, Poole EM, Lehtinen M, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Boutron-Ruault MC, Trichopoulou A, Mattiello A, Onland-Moret NC, Weiderpass E, Sánchez MJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. Cancer Causes Control. 2017; 28(5):429-435. PMCID: PMC5447004.
   • Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Dossus L, Trichopoulou A, Masala G, Onland-Moret NC, Weiderpass E, Duell EJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Trabert B, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT. Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. Cancer Res. 2017 Jul 15; 77(14):3951-3960. PMCID: PMC5512110.
4. Identify how the biologic consequences of psychosocial stress and distress influence carcinogenesis
   
   • Roberts AL, Huang T, Koenen KC, Kim Y, Kubzansky LD, Tworoger SS. Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study. Cancer Res. 2019. PMCID: 31488422.
   • Trudel-Fitzgerald C, Poole EM, Idahl A, Lundin E, Sood AK, Kawachi I, Kubzansky LD, Tworoger SS. The Association of Work Characteristics With Ovarian Cancer Risk and Mortality. Psychosom Med. 2017;79(9):1059-1067. PMCID: PMC5601015.
   • Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS. A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients. Cancer Causes Control. 2016;27(5):661-8. PMCID: 27023470
   • Huang T, Poole EM, Okereke OI, Kubzansky LD, Eliassen AH, Sood AK, Wang M, Tworoger SS. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. Gynecol Oncol. 2015;139(3):481-6. PMCID: PMC4679423.
   • Huang T, Trudel-Fitzgerald C, Poole EM, Sawyer S, Kubzansky LD, Hankinson SE, Okereke OI, Tworoger SS. The Mind-Body Study: Study Design and Reproduciblity and Interrelationships of Psychosocial Factors in the Nurses' Health Study II. Cancer Causes Control. 2019;30(7):779–790. doi:10.1007/s10552-019-01176-0
5. Elucidate the hormonal etiology of breast cancer and integrating biologic markers into risk prediction models, with an ultimate goal of identifying approaches to integrate risk prediction into the clinic.
   
   • Rice MS, Tworoger SS, Hankinson SE, Tamimi RM, Eliassen AH, Willett WC, Colditz G, Rosner B. Breast cancer risk prediction: an update to the Rosner-Colditz breast cancer incidence model. Breast Cancer Res Treat. 2017 Nov;166(1):227-240. PMC5647223.
   • Zhang X, Rice M, Tworoger SS, Rosner BA, Eliassen AH, Tamimi RM, Joshi AD, Lindstrom S, Qian J, Colditz GA, Willett WC, Kraft P, Hankinson SE. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. PLoS medicine. 2018; 15(9):e1002644. PMCID:PMC6122802.
   • Tworoger SS, Zhang X, Eliassen AH, Qian J, Colditz GA, Willett WC, Rosner BA, Kraft P, Hankinson SE. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol. 2014;32(28):3111-7. PMCID:PMC4171356.
   • Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 2013 Aug 1;73(15):4810-9. PMCID: PMC3738582.
   • Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE. Bioactive prolactin levels and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):73-80. PMCID: PMC4294963.